SAM
AMPH icon

Silvercrest Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Silvercrest Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-165,856
Closed -$4.81M – 837
2025
Q1 		$4.81M Sell
165,856
-958
-0.6% -$30.6K 0.03% 409
2024
Q4 		$6.19M Sell
166,814
-1,658
-1% -$75.8K 0.04% 378
2024
Q3 		$8.18M Sell
168,472
-1,104
-0.7% -$48.4K 0.06% 294
2024
Q2 		$6.78M Buy
169,576
+57,148
+51% +$2.37M 0.05% 346
2024
Q1 		$4.94M Buy
112,428
+29,182
+35% +$1.51M 0.03% 392
2023
Q4 		$5.15M Hold
83,246
– – 0.04% 368
2023
Q3 		$3.83M Sell
83,246
-26,401
-24% -$1.44M 0.03% 402
2023
Q2 		$6.3M Sell
109,647
-45,221
-29% -$2M 0.04% 326
2023
Q1 		$5.81M Sell
154,868
-68,290
-31% -$2.24M 0.04% 320
2022
Q4 		$6.25M Sell
223,158
-1,998
-0.9% -$58K 0.05% 299
2022
Q3 		$6.33M Sell
225,156
-6,120
-3% -$200K 0.05% 286
2022
Q2 		$8.05M Sell
231,276
-10,425
-4% -$372K 0.06% 262
2022
Q1 		$8.68M Sell
241,701
-127,250
-34% -$3.61M 0.06% 278
2021
Q4 		$8.59M Hold
368,951
– – 0.05% 288
2021
Q3 		$7.01M Sell
368,951
-8,504
-2% -$167K 0.05% 324
2021
Q2 		$7.61M Buy
377,455
+83,873
+29% +$1.58M 0.05% 315
2021
Q1 		$5.38M Sell
293,582
-39,215
-12% -$729K 0.04% 368
2020
Q4 		$6.69M Buy
332,797
+51,817
+18% +$1.01M 0.05% 310
2020
Q3 		$5.27M Sell
280,980
-5,340
-2% -$108K 0.05% 330
2020
Q2 		$6.43M Sell
286,320
-5,032
-2% -$92.2K 0.06% 267
2020
Q1 		$4.32M Sell
291,352
-8,918
-3% -$155K 0.05% 304
2019
Q4 		$5.79M Buy
300,270
+69,229
+30% +$1.33M 0.04% 319
2019
Q3 		$4.58M Buy
+231,041
New +$4.81M 0.04% 350

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Silvercrest Asset Management's AMPH Position: Q2 2025 in Review

Silvercrest Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 165,856 shares — an estimated $4.81M sold.

Silvercrest Asset Management first reported a position in AMPH in Q3 2019 and held it in 23 quarters. The position peaked at $8.68M in Q1 2022. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Silvercrest Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Silvercrest Asset Management sold 165,856 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $4.81M.
  • Silvercrest Asset Management first reported a position in Amphastar Pharmaceuticals in Q3 2019 and held it in 23 quarters.
  • Silvercrest Asset Management's Amphastar Pharmaceuticals position peaked at $8.68M in Q1 2022.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Silvercrest Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.